| Current Medical Articles |
|---|
 |
TIME Europe
February 15, 2010
Kathleen Kingsbury |
Prescription for a Turnaround New CEO George Barrett gets Cardinal Health refocused on the supply chain.   |
BusinessWeek
February 4, 2010
Dermot Doherty |
The New Man at Novartis CEO Joe Jimenez says his consumer-products background, with stints at Clorox and Heinz, will be a booster for the drugmaker. |
Chemistry World
February 4, 2010
Matt Wilkinson |
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. |
The Motley Fool
February 4, 2010
Brian Orelli |
A Drugless Drugmaker IPO! Biotech investors embrace risk ... sort of. The most exciting thing about Ironwood's IPO? The company doesn't have any drugs on the market. |
The Motley Fool
February 4, 2010
Brian Orelli |
Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last? |
The Motley Fool
February 4, 2010
Brian Orelli |
Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct. |
The Motley Fool
February 3, 2010
Brian Orelli |
Wyeth Can't Save Pfizer Not much earnings growth, but the price is right. |
The Motley Fool
February 3, 2010
Brian Orelli |
Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease. |
InternetNews
February 2, 2010 |
UCSF Patients Latest Data Breach Victims A laptop containing the personal information of more than 4,300 patients receiving care at the University of California, San Francisco medical school was stolen in November. |
The Motley Fool
February 2, 2010
Brian Orelli |
Shaking Up the Biotech Industry A judge will decide if genes are patentable or not. |
The Motley Fool
February 2, 2010
Brian Orelli |
Foolish Forecast: First Look at Pfizer Plus With the addition of Wyeth last quarter, there's no doubt Pfizer is larger, but whether that bigger size translates into savings that boosts profits remains to be seen. |
TIME Europe
February 8, 2010
Bonnie Rochman |
Group Therapy Why so many patients are sharing their medical data online. |
InternetNews
February 1, 2010 |
Apple's iPad a Boon to Health Care Providers? Steve Jobs didn't mention it at the product's debut, but the iPad's specs and design position it as a good point-of-care device for health care professionals and telemedicine applications. |
The Motley Fool
February 1, 2010
Brian Orelli |
Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost. |
CRM
February 2010
Lauren McKay |
The New-Age Home Aided by SiteSpect, a specialist in elder-care placement boosts Web conversions and better addresses client needs. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
January 29, 2010
Brian Orelli |
Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead. |
The Motley Fool
January 29, 2010
Brian Orelli |
Icahn Back to Batter Biogen The old guy has tenacity. |
The Motley Fool
January 29, 2010
Brian Orelli |
All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time. |
Chemistry World
January 28, 2010
Nina Notman |
AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost. |
The Motley Fool
January 28, 2010
Brian Orelli |
Health-Care Reform Is Dead. Probably. Breaking up the bill doesn't seem like the answer. What do insurers and pharmaceutical companies have to say? |
The Motley Fool
January 28, 2010
Brian Orelli |
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. |
The Motley Fool
January 28, 2010
Brian Orelli |
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
January 27, 2010
Brian Orelli |
Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that. |
The Motley Fool
January 27, 2010
Brian Orelli |
Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note. |
The Motley Fool
January 27, 2010
Brian Orelli |
The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs. |
The Motley Fool
January 26, 2010
Brian Orelli |
Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug. |
The Motley Fool
January 26, 2010
Dave Mock |
A Big Upgrade for Cepheid Enough top-performing Motley Fool CAPS members have recently moved to the bull side of Cepheid to upgrade the molecular diagnostics firm from its four-star rank to a top-rated five stars. |
The Motley Fool
January 25, 2010
Brian Orelli |
Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
January 25, 2010
Brian Orelli |
Tysabri Updates: All You Have to Do Is Ask Biogen Idec is willing to hook medical doctors up with an automatic monthly update of the number of progressive multifocal leukoencephalopathy cases for people taking it and Elan's multiple sclerosis drug, Tysabri. |
Nurse Practitioner
February 2010
Jennifer M. Belavic |
Drug approvals '09 in review On May 13, 2009, the FDA approved certolizumab pegol, marketed under the brand name Cimzia, for the treatment of moderately to severely active RA. |
The Motley Fool
January 22, 2010
Brian Orelli |
Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line. |
The Motley Fool
January 22, 2010
Brian Orelli |
Intuitive Surgical Makes Me a Winner! Hysterectomies are poised to pass prostatectomies as the company's growth driver. |
Fast Company
February 2010
Paul Hochman |
Bionic Legs, i-Limbs, and Other Super Human Prosheses You'll Envy Save your tears for Tiny Tim. A boom in sophisticated prostheses has created a most unlikely by-product: envy. |
Fast Company
February 2010
Nathaniel Whittemore |
How Cell Phone-Powered Labs Could Transform Medical Diagnostics in Africa A social enterprise's invention could transform medical diagnostics in the developing world. |
Fast Company
February 2010
Kate Rockwood |
An In-Depth Look at the Hospital of the Future The hospital of the future is designed not just to heal the sick but also to help sustain the environment. |
Philanthropy
January 1, 2010
Adam Keiper |
Breakthrough Medical research is dominated by government and corporate funding. How can philanthropic dollars find a distinctive niche? |
Chemistry World
January 20, 2010
Phil Taylor |
Screw tightens on pay-for-delay drug deals Scrutiny of the tactics used by pharmaceutical companies to delay the entry of generics onto the market is rising on both sides of the Atlantic amid claims that the practice is costing consumers billions every year. |
National Defense
February 2010
Austin Wright |
Deployable Brain Scanner Could Help Treat Soldiers' Head Injuries John E. Kimura, the president and CEO of Sensorium Inc., believes his system will allow neurologists in the United States to peer into the heads of wounded soldiers in remote areas. |
Chemistry World
January 6, 2010
Ned Stafford |
UK libel laws threaten scientific debate A libel lawsuit brought by GE Healthcare has succeeded in silencing an eminent Danish radiologist who questioned the safety of one of the firm's drugs, but the firm is now being accused by some in the scientific community of trying to stifle legitimate scientific discussion. |
| There are 6318 old articles available for this category. |
